文献速递重症综合管理与镇静镇痛心脑血管急症

肠型脂肪酸结合蛋白与急性心力衰竭或心源性休克患者死亡率相关

Intestinal Fatty Acid Binding Protein is Associated With Mortality in Patients With Acute Heart Failure or Cardiogenic Shock.
PubMed 文献 · Shock · 2019-01-01
一句话结论入住心脏ICU的心源性休克或严重急性心衰患者,入院时iFABP≥588.4 pg/mL与2.5倍死亡风险独立相关,≥10208.4 pg/mL者死亡率达88.9%。

该研究连续纳入90例入住心脏ICU的心源性休克(74.4%)或严重急性心衰(25.6%)患者,第0天和第3天采血检测iFABP。第0天iFABP最高四分位(≥588.4 pg/mL)患者死亡风险为2.5倍(P=0.02),独立于人口学、NT-proBNP和升压药使用。入院iFABP超过第90百分位(≥10208.4 pg/mL)与88.9%的过高死亡率相关。第3天iFABP水平与结局无关。提示入院时iFABP可预测死亡,早期小肠灌注不足可能与生存率骤降相关。

要点

  • 入院第0天iFABP最高四分位(≥588.4 pg/mL)患者30天死亡风险为2.5倍(P=0.02),独立于人口学、NT-proBNP和升压药使用。
  • 入院iFABP≥10208.4 pg/mL(第90百分位)者死亡率达88.9%。
  • 第3天iFABP水平与结局无关,提示仅入院时iFABP有预测价值。
  • 研究人群为心脏ICU收治的心源性休克(74.4%)或严重急性心衰(25.6%)患者,30天生存率64.4%。

适用人群与场景

  • 连续纳入90例入住心脏ICU的心源性休克(74.4%)或严重急性心衰(25.6%)患者。
  • 中位年龄64.7(49.4-74.3)岁,76.7%为男性,中位NT-proBNP 4,986(1,525-23,842)pg/mL。
  • 30天生存率64.4%。

研究设计与关键结果

  • 研究类型为队列研究,样本量90例,人群为入住心脏ICU的心源性休克或严重急性心衰患者。
  • 第0天iFABP最高四分位(≥588.4 pg/mL)患者死亡风险为2.5倍(P=0.02),独立于人口学、NT-proBNP水平和升压药使用。
  • 入院iFABP≥10208.4 pg/mL(第90百分位)与88.9%的死亡率相关。
  • 第3天iFABP水平与结局无关。

证据类型、等级与局限

  • 证据类型:队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于入住心脏ICU的心源性休克或严重急性心衰患者,入院时检测iFABP可能有助于识别死亡高风险患者。
  • 作者认为,入院时iFABP可预测死亡,早期小肠灌注不足可能与心源性休克或严重急性心衰患者生存率骤降相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute heart failure and cardiogenic shock are associated with an impaired intestinal perfusion, which may lead to a release of cytoplasmatic proteins by hypoxic epithelial injury. Intestinal fatty acid binding protein (iFABP), highly specific for the small bowel enterocyte, may pose a useful novel and very sensitive biomarker for predicting outcome of these patients.The aim of this study was to investigate whether circulating levels of iFABP are associated with mortality in patients with acute heart failure or cardiogenic shock requiring intensive care unit (ICU) admission.

METHODS: We included 90 consecutive patients with cardiogenic shock (74.4%) or severe acute heart failure (25.6%) admitted to a cardiac ICU. Blood samples were taken at day 0 and day 3. Median age was 64.7 (49.4-74.3), 76.7% of patients were male and median NT-proBNP levels were 4,986 (1,525-23,842) pg/mL. 30-day survival was 64.4%.

RESULTS: Patients with serum levels of iFABP at day 0 in the highest quartile (iFABP ≥ 588.4 pg/mL) had a 2.5-fold risk (P = 0.02) of dying independent of demographics, NT-proBNP levels, and vasopressor use. Extensively elevated admission levels of iFABP above the 90th percentile (iFABP ≥ 10208.4 pg/mL) were associated with an excessive mortality rate of 88.9%. In contrast, iFABP levels at day 3 were not associated with outcome.

CONCLUSION: Circulating levels of iFABP at admission predict mortality. This suggests that early inadequate perfusion of the small intestine may be associated with a dramatically decreased survival in patients with cardiogenic shock or severe acute heart failure.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Kastl SP, Krychtiuk KA, Lenz M, et al. Intestinal Fatty Acid Binding Protein is Associated With Mortality in Patients With Acute Heart Failure or Cardiogenic Shock. Shock. 2019. PMID: 29847500. doi:10.1097/SHK.0000000000001195

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。